Bronstein, Gewirtz & Grossman, LLC Investigates China-Biotics, Inc.

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of China-Biotics, Inc. (“China Biotics” or the “Company”) (NASDAQ GS: CHBT), concerning whether the company and certain of its officers and directors have violated federal securities laws.

On June 15, 2011, NASDAQ halted trading in China-Biotics common stock, a leading developer, manufacturer, and distributor of probiotics products in China. The Company filed for an extension of time to file with the Securities and Exchange Commission its Annual Report on Form 10-K for the fiscal year ended March 31, 2011. NASDAQ has requested that China-Biotics provide certain information and explanation relating to the Company’s delay in filing the Form 10-k.

If you are aware of any facts relating to this investigation, or purchased shares of China- Biotics, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [e-mail]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate work, private securities offerings, and securities arbitration.